{
    "title": "113_s1323",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Protecting Our Youth from Dangerous \nSynthetic Drugs Act of 2013''.\n\nSEC. 2. ENFORCEMENT.\n\n    (a) In General.--The Controlled Substances Act (21 U.S.C. 801 et \nseq.) is amended--\n            (1) in section 102(32), by striking subparagraph (A) and \n        inserting the following:\n            ``(A) Except as provided in subparagraph (C), the term \n        `controlled substance analogue' means--\n                    ``(i) a substance whose chemical structure is \n                substantially similar to the chemical structure of a \n                controlled substance in schedule I or II--\n                            ``(I) which has a stimulant, depressant, or \n                        hallucinogenic effect on the central nervous \n                        system that is substantially similar to or \n                        greater than the stimulant, depressant, or \n                        hallucinogenic effect on the central nervous \n                        system of a controlled substance in schedule I \n                        or II; or\n                            ``(II) with respect to a particular person, \n                        which such person represents or intends to have \n                        a stimulant, depressant, or hallucinogenic \n                        effect on the central nervous system that is \n                        substantially similar to or greater than the \n                        stimulant, depressant, or hallucinogenic effect \n                        on the central nervous system of a controlled \n                        substance in schedule I or II; or\n                    ``(ii) a substance designated as a controlled \n                substance analogue by the Controlled Substance Analogue \n                Committee in accordance with section 201(i).''; and\n            (2) in section 201, by adding at the end the following:\n    ``(i)(1) The Attorney General, in consultation with the Secretary \nof Health and Human Services, shall establish an interagency committee, \nto be known as the Controlled Substance Analogue Committee (referred to \nin this subsection as the `Committee').\n    ``(2) The Committee shall be--\n            ``(A) headed by the Administrator of the Drug Enforcement \n        Administration; and\n            ``(B) comprised of scientific experts in the fields of \n        chemistry and pharmacology from--\n                    ``(i) the Drug Enforcement Administration;\n                    ``(ii) the National Institute on Drug Abuse;\n                    ``(iii) the Centers for Disease Control and \n                Prevention; and\n                    ``(iv) any other Federal agency determined by the \n                Attorney General, in consultation with the Secretary of \n                Health and Human Services, to be appropriate.\n    ``(3)(A) The Committee shall convene, on an as needed basis, to \nestablish and maintain a list of controlled substance analogues.\n    ``(B) A substance may be designated as a controlled substance \nanalogue by the Committee under this subsection if the substance is \ndetermined by the Committee to be similar to a schedule I or II \ncontrolled substance in either its chemical structure or its predictive \neffect on the body, in such a manner as to make it likely that the \nsubstance will, or can be reasonably expected to have a potential for \nabuse.\n    ``(C) Evidence of human consumption by an individual or the public \nat large is not necessary before a substance may be designated as a \ncontrolled substance analogue under this subsection.\n    ``(D) The Attorney General shall, through rulemaking, establish \nprocedures of operation for the Committee.\n    ``(4)(A) Not later than 30 days before each meeting of the \nCommittee, the Attorney General shall submit to the Secretary of Health \nand Human Services a notice of the meeting of the Committee, which \nshall include--\n            ``(i) a list of the substances to be considered by the \n        Committee during the meeting for designation as a controlled \n        substance analogue; and\n            ``(ii) a request for the Secretary of Health and Human \n        Services to make a determination of whether an exemption or \n        approval for each substance listed under clause (i) is in \n        effect under section 505 of the Federal Food, Drug, and \n        Cosmetic Act (21 U.S.C. 355).\n    ``(B) Not later than 30 days after the date on which the Secretary \nof Health and Human Services receives notice under subparagraph (A), \nthe Secretary shall submit to the Attorney General a written response \nto the request described under subparagraph (A)(ii). The Committee \nshall consider the response submitted by the Secretary of Health and \nHuman Services in determining whether to designate a substance \nconsidered by the Committee at the meeting as a controlled substance \nanalogue.\n    ``(5)(A) The Attorney General shall publish in the Federal Register \nany designation made by the Committee under this subsection.\n    ``(B) The Administrator of the Drug Enforcement Administration \nshall publish, on the website of the Drug Enforcement Administration, a \ndescription of each designation made by the Committee under this \nsubsection, which shall include--\n            ``(i) the chemical and common name of the controlled \n        substance analogue;\n            ``(ii) the effective date of the determination, as \n        described in paragraph (6)(A); and\n            ``(iii) any schedule I or II controlled substance that the \n        Committee has determined a substance is an analogue of.\n    ``(6) A designation made by the Committee under this subsection \nshall take effect on the date that is 30 days after the date on which \nthe designation is published in the Federal Register under paragraph \n(5)(A).\n    ``(7) If a substance designated as a controlled substance analogue \nby the Committee under this section is subsequently scheduled through a \nrulemaking proceeding under subsection (a), (d), or (h), the substance \nshall be automatically removed from the controlled substance analogue \nlist.\n    ``(8) If a defendant challenges the designation of a controlled \nsubstance analogue made by the Committee under this subsection the \nissue shall be considered a question of law.''.\n    (b) Funding.--Section 111(b)(2)(B) of Public Law 102-395 (21 U.S.C. \n886a(2)(B)) is amended by inserting ``controlled substance analogues,'' \nafter ``substances,''.\n\nSEC. 3. IMPORTATION OF CONTROLLED SUBSTANCE ANALOGUES.\n\n    Section 1002 of the Controlled Substances Import and Export Act (21 \nU.S.C. 952) is amended--\n            (1) by redesignating subsections (c) through (e) as \n        subsections (d) through (f), respectively; and\n            (2) by inserting after subsection (b) the following:\n    ``(c) It shall be unlawful to import into the customs territory of \nthe United States from any place outside thereof (but within the United \nStates), or to import into the United States from any place outside \nthereof, any controlled substance analogue designated pursuant to \nsection 201(i) of the Controlled Substances Act (21 U.S.C. 811(i)) \nunless the controlled substance analogue is imported pursuant to such \nnotification or declaration as the Attorney General may by regulation \nprescribe.''.\n\nSEC. 4. DIRECTIVE TO SENTENCING COMMISSION.\n\n    (a) In General.--Pursuant to its authority under section 994 of \ntitle 28, United States Code, the United States Sentencing Commission \nshall review and, if appropriate, amend the Federal sentencing \nguidelines and policy statements to ensure the guidelines and policy \nstatements provide adequate penalties for any offense involving the \nunlawful manufacturing, importing, exporting, or trafficking of \ncontrolled substance analogues under part D of the Controlled \nSubstances Act (21 U.S.C. 841 et seq.) or part A of the Controlled \nSubstances Import and Export Act (21 U.S.C. 951 et seq.) and similar \noffenses, including unlawful possession, possession with intent to \ncommit any of the foregoing offenses, and attempt and conspiracy to \ncommit any of the foregoing offenses.\n    (b) Commission Duties.--In carrying out this section, the \nSentencing Commission shall--\n            (1) ensure that the sentences, guidelines, and policy \n        statements relating to offenders convicted of these offenses \n        are appropriately severe and reasonably consistent with other \n        relevant directives and other Federal sentencing guidelines and \n        policy statements;\n            (2) make any necessary conforming changes to the Federal \n        sentencing guidelines; and\n            (3) assure that the guidelines adequately meet the purposes \n        of sentencing as set forth in section 3553(a)(2) of title 18, \n        United States Code."
}